Thera-SAbDab

GLEMBATUMUMAB

>   Structural Summary
TherapeuticGlembatumumab
TargetGPNMB
Heavy ChainQVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS
Light ChainEIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb ADC
IsotypeG2
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Discontinued
Recorded Developmental Technologyna
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedCuraGen Corporation, Celldex Therapeutics Inc, National Cancer Institute (USA)
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedBrain cancer, Breast cancer, Malignant melanoma, Osteosarcoma, Squamous cell cancer, Uveal melanoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]